NoordzijM., KorevaarJ.C., BoeschotenE.W., DekkerF.W., BosW.J., KredietR.T.The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.Am J Kidney Dis2005; 46: 925–32.
2.
StrippoliG.F., PalmerS., TongA., ElderG., MessaP., CraigJ.C.Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.Am J Kidney Dis2006; 47: 715–26.
3.
BlockG.A., MartinK.J., de FranciscoA.L., TurnerS.A., AvramM.M., SuranyiM.G.Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.N Engl J Med2004; 350: 1516–25.
4.
SpragueS.M., EvenepoelP., CurziM.P., GonzálezM.T., HusserlF.E., KopytN.Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl.Clin J Am Soc Nephrol2009; 4: 1465–76.
5.
UreñaP., JacobsonS.H., ZittE., VervloetM., MalbertiF., AshmanN.Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO observational study.Nephrol Dial Transplant2009; 24: 2852–9.
6.
TorresA., LorenzoV., HernándezD., RodríguezJ.C., ConcepciónM.T., RodríguezA.P.Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH.Kidney Int1995; 47: 1434–42.
7.
National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42(Suppl 3): S1–202.
8.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int Suppl2009; (113): S1–130.
9.
BarretoF.C., BarretoD.V., MoysésR.M., NevesK.R., CanzianiM.E., DraibeS.A.K/DOQI-recommended intact-PTH levels do not prevent low-turnover bone disease in hemodialysis patients.Kidney Int2008; 73: 771–7.
10.
MessaP., MacárioF., YaqoobM., BoumanK., BraunJ., von AlbertiniB.The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.Clin J Am Sc Nephrol2008; 3: 36–45.
